2008
Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer
Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt WE, Ranade AA, Cohen G, Trigo JM, Sandler AB, Bonomi PD, Herbst RS, Krebs AD, Vasselli J, Johnson BE. Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer. Journal Of Clinical Oncology 2008, 26: 5407-5415. PMID: 18936474, DOI: 10.1200/jco.2008.17.3138.Peer-Reviewed Original ResearchConceptsProgression-free survivalPhase II studyRisk of progressionVandetanib monotherapyII studyOverall survivalLung cancerAdvanced non-small cell lung cancerNon-small cell lung cancerMedian progression-free survivalLonger progression-free survivalRandomized phase II studyShorter progression-free survivalEnd pointVascular endothelial growth factor receptorCommon adverse eventsPrimary end pointStudy end pointSquamous cell histologyEndothelial growth factor receptorCell lung cancerCNS metastasesGrowth factor receptorMonotherapy armNSCLC histology
2007
Randomized phase II study of vandetanib (VAN) alone or in combination with carboplatin and paclitaxel (CP) as first-line treatment for advanced non-small cell lung cancer (NSCLC)
Heymach J, Paz-Ares L, De Braud F, Sebastian M, Stewart D, Eberhardt W, Herbst R, Krebs A, Langmuir P, Johnson B. Randomized phase II study of vandetanib (VAN) alone or in combination with carboplatin and paclitaxel (CP) as first-line treatment for advanced non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2007, 25: 7544-7544. DOI: 10.1200/jco.2007.25.18_suppl.7544.Peer-Reviewed Original ResearchNon-small cell lung cancerProgression-free survivalAdvanced non-small cell lung cancerRandomized phase II trialPhase II trialOverall survivalII trialMedian progression-free survivalRandomized phase II studyCTC grade 2Daily oral agentObjective response ratePlasma angiogenic factorsPhase II studyFirst-line treatmentCell lung cancerExploratory subgroup analysisFemale ptsCNS metastasesEligible patientsMonotherapy armSecondary endpointsSquamous histologyII studyOral agents
2006
A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results
Heymach J, Johnson B, Prager D, Csada E, Roubec J, Pesek M, Spasova I, Hou J, Kennedy S, Herbst R. A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results. Journal Of Clinical Oncology 2006, 24: 7016-7016. DOI: 10.1200/jco.2006.24.18_suppl.7016.Peer-Reviewed Original ResearchProgression-free survivalAdverse eventsDose interruptions/reductionsMedian progression-free survivalAsymptomatic QTc prolongationCommon adverse eventsDaily oral agentPhase II trialDouble-blind studyOverall survival dataPhase III evaluationPlatinum-based chemotherapyCell lung cancerExploratory subgroup analysisLung cancer histologyRET receptor tyrosine kinaseCNS metastasesPFS prolongationMetastatic NSCLCII trialOral agentsOverall survivalQTc prolongationFatal episodesSubgroup analysis